Vectus Biosystems (ASX:VBS) Retained Earnings : A$-36.81 Mil (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Vectus Biosystems Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Vectus Biosystems's retained earnings for the quarter that ended in Dec. 2023 was A$-36.81 Mil.

Vectus Biosystems's quarterly retained earnings declined from Dec. 2022 (A$-34.32 Mil) to Jun. 2023 (A$-35.63 Mil) and declined from Jun. 2023 (A$-35.63 Mil) to Dec. 2023 (A$-36.81 Mil).

Vectus Biosystems's annual retained earnings declined from Jun. 2021 (A$-29.13 Mil) to Jun. 2022 (A$-32.18 Mil) and declined from Jun. 2022 (A$-32.18 Mil) to Jun. 2023 (A$-35.63 Mil).

Vectus Biosystems Retained Earnings Historical Data

The historical data trend for Vectus Biosystems's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vectus Biosystems Retained Earnings Chart

Vectus Biosystems Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Retained Earnings

Get a 7-Day Free Trial

-21.85

-24.84

-29.13

-32.18

-35.63

Vectus Biosystems Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Retained Earnings	Get a 7-Day Free Trial											-31.67	-32.18	-34.32	-35.63	-36.81

Vectus Biosystems Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Vectus Biosystems (ASX:VBS) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Vectus Biosystems Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vectus Biosystems Ltd (ASX:VBS) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

N/A

Address

3-11 Primrose Avenue, Rosebery, Sydney, NSW, AUS, 2018

Website

https://www.vectusbiosystems.com.au

Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company is in the process of developing a treatment for fibrosis and high blood pressure, which includes heart, kidney, and liver diseases. The company has also developed a technology aimed at improving the speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories.

Vectus Biosystems Headlines

No Headlines